RCM
YMAB

Riverhead Capital Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Riverhead Capital Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,380
Closed -$63K – 1570
2018
Q3 		$63K Buy
+2,380
New +$60.5K ﹤0.01% 1464

Other funds holding YMAB

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Riverhead Capital Management's YMAB Position: Q4 2018 in Review

Riverhead Capital Management sold out of Y-mAbs Therapeutics (YMAB) in Q4 2018, closing a stake of 2,380 shares — an estimated $63K sold.

Riverhead Capital Management first reported a position in YMAB in Q3 2018 and held it in 1 quarter. The position peaked at $63K in Q3 2018. 42 funds tracked by Wall St. Rank hold YMAB as of Q4 2018.

  • Riverhead Capital Management reported no remaining Y-mAbs Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Riverhead Capital Management sold 2,380 Y-mAbs Therapeutics shares in Q4 2018, an estimated $63K.
  • Riverhead Capital Management first reported a position in Y-mAbs Therapeutics in Q3 2018 and held it in 1 quarter.
  • Riverhead Capital Management's Y-mAbs Therapeutics position peaked at $63K in Q3 2018.
  • 42 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2018.

Based on Riverhead Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.